Company News
BridgeBio Up 10% After FDA Fast Track
BridgeBio Oncology Therapeutics shares jumped about 10% in after‑hours trading after FDA’s Fast Track designation for BBO‑11818.
The Fast Track status aims to speed development of the pan‑KRAS inhibit
